Stockscreener 앱 받기
22.58
0.70%
-0.16
시간 외 거래:
22.58
전일 마감가:
$22.74
열려 있는:
$22.93
하루 거래량:
1.14M
Relative Volume:
0.88
시가총액:
$2.70B
수익:
$22.57M
순이익/손실:
$-212.73M
주가수익비율:
-12.51
EPS:
-1.8045
순현금흐름:
$-142.19M
1주 성능:
+0.40%
1개월 성능:
-17.41%
6개월 성능:
-27.18%
1년 성능:
-14.11%
1일 변동 폭
$22.35
$22.96
1주일 범위
$21.68
$23.73
52주 변동 폭
$21.02
$42.20
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
명칭
Newamsterdam Pharma Company Nv
전화
35 206 2971
주소
GOOIMEER 2-35, NARRDEN
Compare NAMS vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
22.58 | 2.70B | 22.57M | -212.73M | -142.19M | -1.8045 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-18 | 개시 | Truist | Buy |
| 2025-10-20 | 재개 | H.C. Wainwright | Buy |
| 2025-08-25 | 개시 | Wells Fargo | Overweight |
| 2025-07-17 | 개시 | Goldman | Neutral |
| 2025-06-17 | 개시 | Citigroup | Buy |
| 2025-06-10 | 개시 | Stifel | Buy |
| 2025-06-04 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-05-15 | 개시 | TD Cowen | Buy |
| 2024-03-14 | 개시 | Scotiabank | Sector Outperform |
| 2024-01-18 | 개시 | Guggenheim | Buy |
| 2024-01-16 | 개시 | Piper Sandler | Overweight |
| 2023-10-30 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Newamsterdam Pharma Company Nv 주식(NAMS)의 최신 뉴스
NewAmsterdam Pharma Company N.V. (NAMS) Stock Price, News, Quote & History - Yahoo! Finance Canada
NewAmsterdam Pharma (NAMS) Wins EU Approvals. Can Cholesterol Pills Drive Royalties? - insidermonkey.com
NewAmsterdam, Menarini Secure EU Approval for Obicetrapib-Based Ubeslo and Evlarco - BioPharma APAC
Five Frazier funds detail their NewAmsterdam (NASDAQ: NAMS) positions - Stock Titan
(NAMS) Volatility Zones as Tactical Triggers - Stock Traders Daily
NewAmsterdam Pharma wins EU approval for obicetrapib as Ubeslo and Evlarco - TradingView
EU clears NewAmsterdam Pharma (NAMS) cholesterol drug, unlocking milestone payouts with its partner - Stock Titan
Stifel reiterates NewAmsterdam Pharma stock rating on EU approval - Investing.com
Menarini Group and NewAmsterdam Pharma Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination) - prnewswire.com
Two new cholesterol drugs get their first global approval in Europe - Stock Titan
NAMS Q2 2026 Earnings: Wider-Than-Expected Loss as Clinical-Stage Spending ContinuesProfit Recovery Report - dars.gov.et
NewAmsterdam Pharma (NAMS) Stock Looks Above Fair Value After Its 139% Run - Yahoo Finance
(NAMSW) Movement as an Input in Quant Signal Sets - Stock Traders Daily
NewAmsterdam Pharma stock rises as CEO buys $226.5K in stock By Investing.com - za.investing.com
NewAmsterdam Pharma stock rises as CEO buys $226.5K in stock - Investing.com
NewAmsterdam Pharma (NAMS) CEO adds to stake with fresh share purchase - Stock Titan
Precision Trading with Newamsterdam Pharma Company N.v. (NAMS) Risk Zones - Stock Traders Daily
NewAmsterdam Pharma at Cantor conference: obicetrapib nears key test - Investing.com
NewAmsterdam Pharma at Cantor conference: obicetrapib nears key test By Investing.com - Investing.com UK
Newamsterdam Pharma stock hits 52-week low at 23.02 USD By Investing.com - Investing.com Australia
NewAmsterdam Pharma at Wells Fargo conference: obicetrapib push By Investing.com - Investing.com UK
NewAmsterdam Pharma (NAMS) director sells shares to cover tax bill - Stock Titan
Newamsterdam Pharma stock hits 52-week low at 23.02 USD - investing.com
NewAmsterdam Pharma: Potential Coupled With Uncertainty (NASDAQ:NAMS) - Seeking Alpha
Stifel reiterates Buy on NewAmsterdam Pharma stock after trial failure By Investing.com - Investing.com Nigeria
Stifel reiterates Buy on NewAmsterdam Pharma stock after trial failure - Investing.com
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Benzinga
Price to earnings forward of NewAmsterdam Pharma Company N.V. – BOATS:NAMSW - TradingView
Why (NAMSW) Price Action Is Critical for Tactical Trading - Stock Traders Daily
NewAmsterdam Pharma Company N.V. - Reuters
NewAmsterdam Pharma VP Robert Gunning Granted 3,200 RSUs and 14,000 Stock Options - Kalkine Media
NewAmsterdam Pharma (NAMS) awards 14,000 options and 3,200 RSUs to controller - Stock Titan
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
NAMS Q2 2026 Earnings: Quarterly Net Loss Widens Slightly on R&D InvestmentPre-Earnings Setup - vinanet.vn
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September - The Manila Times
NAMSW Warrant Holds Flat at $16.51 as Consolidation Persists Below $17.34 ResistanceVolatility Term Structure - dars.gov.et
NewAmsterdam Pharma Company NV (NAMS) Valuation: PE, PB & Fair Value Analysis - TradingKey
NewAmsterdam Pharma Company N.V. Warrant (NASDAQ: NAMSW) Stock Price, News & Analysis - kalkine.ca
NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026 - Barchart.com
NewAmsterdam Pharma (NASDAQ: NAMS) affiliate plans Nasdaq share sale over 90 days - Stock Titan
NewAmsterdam Pharma (NASDAQ: NAMS) affiliate readies Nasdaq share sale - Stock Titan
NewAmsterdam (NAMSW) Shares: Moves 3.19% Higher to $16.51; Level Watch: the Price Remains Bounded by the Supplied Support and Resistance in the Latest ReadingFactor Momentum - vinanet.vn
NewAmsterdam (NAMS) Earnings Update: The EPS Result Is Below Expectation in Latest Trading; Investor Response: Shares Close 4.70% Higher on the DayEarnings Acceleration Picks - vinanet.vn
NewAmsterdam (NAMSW) Shares: Shows Minimal Net Change at $16.00 in Latest Trading; Trading Range: Support at $15.20 and Resistance at $16.80 Frame the Range in the Latest SessionSingle Stock ETF - vinanet.vn
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
How Investors Are Reacting To NewAmsterdam Pharma (NAMS) Plunging Sales And Deepening Losses - Sahm
NewAmsterdam Pharma Company N.V. $NAMS Shares Acquired by Bank of America Corp DE - MarketBeat
NewAmsterdam Pharma Company N.V. $NAMS Shares Sold by Handelsbanken Fonder AB - MarketBeat
NewAmsterdam Pharma Warrant (NAMSW) Flat at $16.72 as Range-Bound Trading PersistsVolume Breadth - vinanet.vn
NewAmsterdam Pharma Warrant (NAMSW) Holds Ground at $16.72 as Trading Range TightensAAII Neutral - vinanet.vn
NewAmsterdam Pharma (NAMS) outlines Douglas Kling separation and advisory deal - Stock Titan
Newamsterdam Pharma Company Nv (NAMS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.06%
2.55%
자본화:
|
볼륨(24시간):